Recruiting nowPhase 1/2Ages 18 Years and up

Proton or Photon RT for Retroperitoneal Sarcomas

Sponsor: Massachusetts General Hospital · NCT01659203 on ClinicalTrials.gov ↗

Bring this to your care team →

Conditions studied

Retroperitoneal Sarcoma

What it tests

IG-IMPTradiation
IG IMRTradiation

Where it's running10 sites

Rush University Medical Center
Chicago, Illinois 60612
Recruiting now
- Dian Wang, MD(contact)[email protected]
Massachusetts General Hospital
Boston, Massachusetts 02114
Recruiting now
- Thomas DeLaney, MD(contact)6177266876 [email protected]
- Thomas DeLaney, MD(principal investigator)
Dana-Farber Cancer Institute
Boston, Massachusetts 02115
Recruiting now
- Elizabeth Baldini, MD, MPH(contact)6177326310 [email protected]
- Elizabeth Baldini, MD, MPH(principal investigator)
Mayo Clinic
Rochester, Minnesota 55902
Recruiting now
- Ivy Peterson, MD(contact)[email protected]
Washington University School of Medicine Siteman Cancer Center West County
Creve Coeur, Missouri 63141
Recruiting now
- Jeff Michalski, MD(contact)[email protected]
Washington University School of Medicine Siteman Cancer Center South County
St Louis, Missouri 63129
Recruiting now
- Jeff Michalski, MD(contact)[email protected]
Roswell Park Cancer Institute
Buffalo, New York 14263
Recruiting now
- Varun Chowdhry, MD(contact)mailto:[email protected]
- Varun Chowdhry, MD(principal investigator)
Duke University
Durham, North Carolina 27710
Recruiting now
- Trey Blazer, MD(contact)[email protected]
MD Anderson Cancer Center
Houston, Texas 77030
Recruiting now
- Andrew Bishop, MD(contact)
- Andrew Bishop, MD(principal investigator)
University of Utah
Salt Lake City, Utah 84112
Recruiting now
- Ying Hitchcock, MD(contact)[email protected]

See the official eligibility language

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* Histologically proven primary soft tissue sarcoma of the retroperitoneum
* Measurable disease
* Life expectancy of greater than 2 years

Exclusion Criteria:

* Prior radiation therapy for retroperitoneal sarcoma
* Pregnant or breastfeeding
* Chemotherapy within 4 weeks prior to entering study
* Receiving other investigational agents
* Other types of sarcomas
* Multifocal disease, lymph node or distant metastases
* History of sensitivity to radiation therapy
* Uncontrolled intercurrent illness
* History of a different invasive malignancy within the past 3 years
* HIV positive on combination anti-retroviral therapy

Updated 2026-03-19 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.